MDUFA III is a game changer for US industry, but concern grows over FDA funding
This article was originally published in Clinica
Executive Summary
The US devices tax naturally dominates US industry’s day-to-day thinking, but it’s not the only pressing issue on the agenda. AdvaMed’s chairman for the past year, David Dvorak, believes that the user fees legislation,